At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Fluvoxamine and Placebo for Covid19 and Coronavirus. Completed, enrolled 670 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. People around the United States and Canada can participate.
Study Details
Timeline
Interventions
Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
Will take 2 capsules per day as tolerated for approximately 15 days